KR101751804B1 - mRNA nanoparticles and manufacturing method thereof - Google Patents
mRNA nanoparticles and manufacturing method thereof Download PDFInfo
- Publication number
- KR101751804B1 KR101751804B1 KR1020150134281A KR20150134281A KR101751804B1 KR 101751804 B1 KR101751804 B1 KR 101751804B1 KR 1020150134281 A KR1020150134281 A KR 1020150134281A KR 20150134281 A KR20150134281 A KR 20150134281A KR 101751804 B1 KR101751804 B1 KR 101751804B1
- Authority
- KR
- South Korea
- Prior art keywords
- messenger rna
- nanoparticles
- expression
- plasmid dna
- specific protein
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
Abstract
The present invention relates to nanoparticles which are introduced into a cell to express a specific protein and a method for producing the nanoparticle, and more particularly to a nanoparticle comprising a messenger RNA containing a repeated base sequence for expressing a specific protein, It is formed by twisting and tangling, promoting the expression of a specific protein capable of stimulating the immune system of the cell, thereby inducing an intracellular immune response and treating various diseases. It is possible not only to transmit the plasmid DNA itself, It is possible to omit the process of passage of the nuclear rearrangement and improve the efficiency of protein expression, and it can be safely used because it is composed only of messenger RNA which is a biomaterial and is not toxic to the body, is self-assembled and resistant to nucleic acid degradation, To generate nanoparticles through the one-step process (RCT). The present invention relates to messenger RNA nanoparticles which can be conveniently and economically manufactured by omitting the capping process at the 5 'end and the polyadenylation at the 3' end, and a method for producing the same.
Description
The present invention relates to nanoparticles which are introduced into a cell to express a specific protein and a method for producing the nanoparticle, and more particularly to a nanoparticle comprising a messenger RNA containing a repeated base sequence for expressing a specific protein, It is formed by twisting and tangling, promoting the expression of a specific protein capable of stimulating the immune system of the cell, thereby inducing an intracellular immune response and treating various diseases. It is possible not only to transmit the plasmid DNA itself, It is possible to improve the protein expression efficiency by omitting the post nuclear membrane passage process and to effectively perform protein expression without the capping process of the 5 'end and the polyadenylation process of the 3' end, which are considered to be essential for protein expression using the messenger RNA in vivo It is composed of messenger RNA, a biomaterial, and is not toxic to the body. , Which can be used to generate nano-particles through self-assembly and resistance to nucleic acid degradation, and relatively small plasmid DNAs through one-step process (RCT) Nanoparticles and a method for producing the same.
The target protein expression by the genetic transduction is accomplished through DNA transcription process and messenger RNA translation process. The target protein is selected mainly as a substance capable of stimulating the immune system of the cell, and by promoting the expression of the protein, an intracellular immune response can be generated to obtain a therapeutic effect of various diseases. For this purpose, studies on the transfer of plasmid DNA containing genetic information have been widely carried out. However, since the plasmid DNA that has also transferred the plasmid DNA is transcribed from the inner nuclear membrane into the messenger RNA, and then the nucleus is re-exported to the target protein, the efficiency of passage through the nuclear membrane is very low. Is significantly reduced. In addition, there is a problem that inherent genetic information of a cell is changed due to external genetic information injected into newly dividing cells by a mechanism of intracellular fission. Therefore, in order to solve the problem caused by the transfer of the plasmid DNA, coating materials such as positively charged macromolecules such as the following articles and techniques using lipids as particle constituents have been developed.
<Articles>
R. Tachibana, H. Harashima, Y. Shinohara, H. Kiwada, Adv. Drug Delivery Rev. 2001, 52, 219-226.
However, most of the organic and inorganic materials used are exogenous substances, and when they are ingested into cells, they are recognized as foreign substances and have intracellular toxicity.
SUMMARY OF THE INVENTION The present invention has been made to solve the above problems,
It is an object of the present invention to provide messenger RNA nanoparticles which can induce an intracellular immune response to treat various diseases by promoting the expression of a specific protein capable of stimulating the immune system of cells, and a method for producing the same.
In addition, the present invention provides a messenger RNA nanoparticle capable of omitting the post-transcriptional nuclear transfer process by transferring the messenger RNA and not the plasmid DNA itself, thereby improving protein expression efficiency and a method for producing the same. There is a purpose.
It is another object of the present invention to provide messenger RNA nanoparticles composed of only messenger RNA which is a biomaterial and can be safely used because there is no toxicity in the body and a method for producing the same.
It is another object of the present invention to provide a messenger RNA nanoparticle which is self-assembled through a tangling and twisting process of messenger RNA strands and is resistant to a nucleic acid degrading enzyme, RNase, and a method for producing the same.
In addition, the present invention does not require the capping of the 5 'end and the polyadenylation of the 3' end in the process of generating the messenger RNA nanoparticles, and does not require the use of the relatively small plasmid DNA, The present invention provides messenger RNA nanoparticles that can be manufactured conveniently and economically, and a method for producing the same.
In order to achieve the above object, the present invention is implemented by the following embodiments.
According to one embodiment of the present invention, the messenger RNA nanoparticles according to the present invention are composed of messenger RNA containing a repeated base sequence for the expression of a specific protein, and the capping process at the 5 ' It is characterized by having no 5'-cap structure and 3'-tail structure because it does not undergo the polyadenylation process of the terminal.
According to another embodiment of the present invention, the messenger RNA nanoparticles according to the present invention are characterized by having a spherical shape.
According to another embodiment of the present invention, the messenger RNA nanoparticles according to the present invention have a diameter of 30 to 200 nm.
According to another embodiment of the present invention, the messenger RNA nanoparticles according to the present invention are characterized in that a single strand of messenger RNA is formed by twining and tangling, and is resistant to nucleic acid degrading enzymes.
According to another embodiment of the present invention, there is provided a method for preparing messenger RNA nanoparticles according to the present invention, comprising the steps of: generating a DNA comprising a nucleotide sequence containing genetic information for specific protein expression; A transcription step of transcribing said DNA with an RNA polymerase to produce a single stranded messenger RNA comprising a repeated base sequence for expression of a specific protein; And a self-assembly step in which the single stranded messenger RNA is twisted and tangled to form messenger RNA nanoparticles through self-assembly. In the method of manufacturing the particles, a capping process at the 5 'end and a polyadenylation process at the 3' It does not go through.
According to another embodiment of the present invention, in the method for producing messenger RNA nanoparticles according to the present invention, the DNA is circular double stranded plasmid DNA.
According to another embodiment of the present invention, in the method for producing messenger RNA nanoparticles according to the present invention, the DNA may further include a promoter region sequence and a ribosome binding base sequence for polymerizing an RNA polymerase .
According to another embodiment of the present invention, in the method for producing messenger RNA nanoparticles according to the present invention, in the DNA production step, a promoter region sequence, a ribosome binding base sequence, a specific protein expression A circular double-stranded plasmid DNA containing a nucleotide sequence containing genetic information for the nucleotide sequence of SEQ ID NO.
According to another embodiment of the present invention, in the method for producing messenger RNA nanoparticles according to the present invention, the single stranded messenger RNA is generated by rolling circle transfer.
According to another embodiment of the present invention, in the method for producing messenger RNA nanoparticles according to the present invention, 1 to 5 nM of the plasmid DNA is used.
According to the present invention, the following effects can be obtained by this embodiment.
The present invention promotes the expression of a specific protein capable of stimulating the immune system of a cell, thereby causing an intracellular immune response and treating various diseases.
In addition, the present invention is capable of omitting the post-transcriptional nuclear transfer process by delivering the messenger RNA, rather than delivering the plasmid DNA itself, thereby improving the protein expression efficiency.
In addition, the present invention has an effect that it can be used safely because it is composed only of messenger RNA which is a biomaterial and is not toxic in the body.
In addition, the present invention has an effect that the messenger RNA strands are self-assembled through the tangling and twisting process, and are resistant to the nucleic acid degrading enzyme RNase.
In addition, the present invention does not require the capping of the 5 'end and the polyadenylation of the 3' end in the process of generating the messenger RNA nanoparticles, and does not require the use of the relatively small plasmid DNA, It is possible to achieve convenience and economical efficiency in the manufacturing process.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a schematic view for explaining a process of forming messenger RNA nanoparticles using plasmid DNA; FIG.
FIG. 2 is a graph showing dynamic light scattering analysis results of messenger RNA nanoparticles according to plasmid DNA concentration. FIG.
Fig. 3 is an electron micrograph of messenger RNA nanoparticles according to plasmid DNA concentration. Fig.
FIG. 4 is a scanning electron microscope and atomic force microscope photograph of messenger RNA nanoparticles according to an embodiment of the present invention. FIG.
Figure 5 is a chart showing gel electrophoresis results to identify constituents of messenger RNA nanoparticles.
FIG. 6 is a diagram showing image cytometry results for confirming the components of messenger RNA nanoparticles. FIG.
FIG. 7 is a chart showing gel electrophoresis results for confirming nucleic acid enzyme resistance of messenger RNA nanoparticles. FIG.
8 and 9 are fluorescence microscopic photographs for confirming the protein expression ability of the messenger RNA nanoparticles.
FIG. 10 is a chart showing the results of Cytometry analysis to confirm the protein expression ability of messenger RNA nanoparticles. FIG.
Hereinafter, messenger RNA nanoparticles according to the present invention and a method for producing the same will be described in detail with reference to the accompanying drawings. Unless defined otherwise, all terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs and, if conflict with the meaning of the terms used herein, It follows the definition used in the specification. Further, the detailed description of known functions and configurations that may unnecessarily obscure the subject matter of the present invention will be omitted. Throughout the specification, when an element is referred to as "including " an element, it is understood that the element may include other elements as well, without departing from the other elements unless specifically stated otherwise.
The present invention relates to a messenger RNA nanoparticle which is introduced into a cell and promotes the expression of a specific protein. The messenger RNA nanoparticle includes a repeated base sequence for the expression of a specific protein. The messenger RNA nanoparticle has a certain shape But preferably has a spherical shape as a whole and has a diameter of 30 to 200 nm. The messenger RNA nanoparticles are formed as a single strand of messenger RNA is twisted and tangled with each other. The protein that promotes the expression of the messenger RNA nanoparticles stimulates the immune system of the cell, so that the intracellular immune response can be induced through the injection of the messenger RNA nanoparticles to treat various diseases. The messenger RNA nanoparticles consist of only biomaterials and are not toxic to the body. They can eliminate the process of passing the nuclear membrane during protein expression and have resistance to nucleic acid degrading enzyme (RNase), thereby improving protein expression efficiency. In addition, the messenger RNA nanoparticles have a 5'-cap structure and a 3'-poly A tail structure by omitting the capping process at the 5 'end and the polyadenylation process at the 3' end in the process of protein expression from the messenger RNA in vivo And the manufacturing process is simple, so that the manufacturing cost can be reduced.
A method for producing messenger RNA nanoparticles as described above will be described below. The messenger RNA nanoparticles are preferably prepared by the following production method, but are not limited thereto.
The method for producing the messenger RNA nanoparticles comprises the steps of: preparing a promoter, which is a binding site at which the RNA polymerase starts polymerization at the time of transcription, a ribosomal binding site (RBS), which is a ribosome binding site of the generated messenger RNA, Stranded plasmid DNA comprising a nucleotide sequence encoding a nucleotide sequence encoding the double-stranded plasmid DNA; A transcription step of transcribing the plasmid DNA using an RNA polymerase to produce a long single stranded messenger RNA containing a repeated base sequence for expression of a specific protein; And incubating the reaction solution containing the single stranded messenger RNA at a predetermined temperature for a predetermined time so that the messenger RNA of the single strand is twisted and tangled to form messenger RNA nanoparticles through self-assembly . In the method for preparing messenger RNA nanoparticles, the capping process at the 5 'end and the polyadenylation process at the 3' end are omitted, thereby simplifying the manufacturing process.
In the DNA production step, a DNA containing genetic information of a protein to be expressed is generated. In the DNA production step, a promoter region for polymerization of an RNA polymerase and a ribosomal binding sequence ) And a nucleotide sequence containing genetic information for expression of a specific protein (for example, green fluorescence protein, GFP) are sequentially generated in a circular double-stranded plasmid DNA. Plasmid DNA for specific protein expression is transcribed and self-assembled to form messenger RNA nanoparticles, and the messenger RNA nanoparticles are introduced into human cells to express specific proteins.
In the transcription step, the plasmid DNA generated in the DNA production step is subjected to rolling circle transcription (RCT) using an RNA polymerase to obtain a long DNA sequence containing a repeated nucleotide sequence for the expression of a specific protein This is the step of generating single stranded messenger RNA.
The self-assembling step includes incubating the single-stranded messenger RNA-containing reaction solution at a predetermined temperature for a predetermined period of time, so that the single-stranded messenger RNA is twisted and tangled with each other to self-assemble the messenger RNA nanoparticles . In the self-assembly step, the messenger RNA strands are self-assembled through the tangling and twisting process, so that they are resistant to the nucleic acid degrading enzyme RNase. In the process of preparing the messenger RNA nanoparticles, the diameter of the messenger RNA nanoparticles containing the genetic information on the desired target protein can be controlled by controlling the amount of the plasmid DNA. As will be described in detail below, when the plasmid DNA and the RNA polymerase are mixed and reacted at a predetermined time and temperature, the RNA polymerase forms a long single-stranded messenger RNA through the RCT process as shown in FIG. Since the messenger RNA nanoparticles are generated by self-assembly while gradually twisting and tangling, messenger RNA nanoparticles can be easily generated with a small plasmid DNA using a one-step RCT. In order to protect the mRNA from protein expression from conventional messenger RNAs, 5 'end capping process and 3' end polyadenylation process are carried out after mRNA transcription to prevent protein expression. And the 3 'terminal polyadenylation process. The present invention relates to a method for producing a single-stranded messenger RNA, which comprises stranding a single strand of a messenger RNA to form nanoparticles through self-assembly, In the method for producing RNA nanoparticles, the protein can be effectively expressed by omitting the capping process at the 5 'end and the polyadenylation process at the 3' end, thereby simplifying the manufacturing method and achieving economical efficiency.
Hereinafter, the present invention will be described in more detail with reference to Examples. However, these are only for the purpose of illustrating the present invention in more detail, but the scope of the present invention is not limited thereto.
Example 1 Preparation of Plasmid DNA
(SEQ ID NO: 1) containing the genetic information for green fluorescent protein expression and an eukaryotic ribosomal binding sequence (RBS) known as the Kozak sequence No. 2) and the promoter region base sequence (SEQ ID NO: 3) for T7 RNA polymerase.
≪ Base sequence of plasmid DNA >
Example 2: Preparation of messenger RNA nanoparticles
Reaction buffer (8 mM Tris-HCl, 0.4 mM spermidine, 1.2 mM MgCl 2 , and 2 mM dithiothreitol), 50 units ml -1 of T7 RNA polymerase ( 1 mM), 1 mM of the plasmid DNA produced in Example 1, 4 mM of ribonucleotide solution mix New England Biolabs) were mixed in a tube, and the tube was placed in an incubator and reacted at 37 ° C for 20 hours to prepare messenger RNA nanoparticles (hereinafter referred to as "mRNA-NPs").
<Example 3> Size and distribution of messenger RNA nanoparticles according to plasmid DNA concentration
1) The messenger RNA nanoparticles were prepared by changing the plasmid DNA concentration to 0.05 nM, 0.11 nM, 0.57 nM, 5.00 nM, and 25.00 nM in the production method of Example 2.
2) The results are shown in FIG. 2 by dynamic light scattering analysis (Particle Size Analyzer WI30i) for the messenger RNA nanoparticles prepared in 1) of Examples 2 and 3, and 1 nM, 5 nM and 25 nM plasmid DNA FIG. 3 shows an electron micrograph of the nanoparticles prepared by the above method.
2) As shown in FIGS. 2 and 3, when the concentration of the plasmid DNA is 0.05 nM or less, the nanoparticles are not formed. When the concentration of the plasmid DNA is 0.11 nM or more, the nanoparticles have a diameter of 30 to 200 nm. Generally, the diameters are increased, but after the concentration of the plasmid DNA exceeds 5 nM, the increase in the nanoparticle diameter and number is not large. The present invention aims at producing nanoparticles using a small amount of plasmid DNA, and preferably nanoparticles having a diameter of about 100 nm are preferred for cell penetration and pharmacological effects, so that 1 to 5 nM of plasmid DNA is preferably used .
Example 4: Size and morphology of messenger RNA nanoparticles
(Agarose gel electrophoresis, Park NX10 (Park Systems)) using an SEM (scanning electron microscope, XL30-FEG (FEI)) and AFM (atomic force microscope) of the messenger RNA nanoparticles (5.00 nM of plasmid DNA) prepared in 1) Respectively. Spherical nanoparticles having a diameter of 100 to 200 nm can be identified from an SEM photograph (scale bar, 100 nm) of FIG. 4 a). It can be confirmed that the AFM photograph of FIG. 4 b) has a particle shape that is consistent with the SEM photograph.
Example 5: Identification of constituents of messenger RNA nanoparticles
1) Nanoparticles were prepared in the same manner as in Example 2 except that a ribonucleotide solution mix containing Cyanine 3-UTP (Enzo) was used. The concentrations of cyanine 3-UTP used were 5, 20 and 100 μM, respectively.
2) The nanoparticles prepared in 1) of Example 5 were incubated at room temperature under a condition of 1.2 wt% agarose gel in Tris-acetate-EDTA (TAE) buffer (40 mM Tris-acetate and 1 mM EDTA, pH 8.0 Biosesang) Gel electrophoresis was carried out, and the result was shown in Fig. 5 (a). In addition, the nanoparticles prepared in 1) of Example 5 were incubated at room temperature under a condition of 1.2 wt% agarose gel in Tris-acetate-EDTA (TAE) buffer (40 mM Tris-acetate and 1 mM EDTA, pH 8.0 Biosesang) After dying with GelRed, gel electrophoresis was carried out and the result was shown in Fig. 5 (b).
3) Using the image cytometry of the nanoparticles prepared in the same manner as in Example 5, 1), it is shown in FIG. The concentrations of cyanine 3-UTP used were 0 (control), 5, and 20 μM, respectively.
4) By performing an RCT reaction in conjunction with Cy3-UTP, the nanoparticles are labeled with Cy3-UTP having an orange fluorescent wavelength, so that the nanoparticles are easily visually recognized under ultraviolet light. As shown in FIGS. 5 a) and 5 b), nanoparticles containing Cyanine 3-UTP are visually recognizable (see
Example 6: Confirmation of resistance to nucleic acid degrading enzyme
1) 50 ng of capped mRNA (1800 bp) (hereinafter referred to as Naked mRNA) containing a base sequence for Xef-1 protein expression and 0.54 amole (12 μg) of messenger RNA nanoparticles (mRNA- The cells were mixed with 10% FBS (fetal bovine serum, having a nucleic acid degrading enzyme), incubated at 37 ° C for 5 min and 1 hr, and then subjected to gel electrophoresis on 1% agarose gel to show Lane 1 (control (cntl)),
2) It can be seen from FIG. 7 that long-stranded Naked mRNA is easily degraded according to the concentration of nucleic acid degrading enzyme and reaction time. However, the mRNA-NPs formed by the stranded RNA strands are decomposed to some extent by the degrading enzyme It can be seen that a relatively large amount still remains. This demonstrates that messenger RNA nanoparticles are resistant to lytic enzymes.
<Example 7> Evaluation of protein expression ability of messenger RNA nanoparticles
1) PC-3 cells were cultured in RPMI 1640 (Welgene) supplemented with 10% fetal bovine serum (Gibco), 100 units ml -1 of penicillin, 100 μg ml -1 of streptomycin and 1% antibiotic-antimycotic in humidified atmosphere with 5% CO 2 it is grown at a temperature of 37 ℃. For 24 hours before transfection, the cells are trypsinized with fresh medium (3 × 10 5 cells ml -1 ), diluted and transferred to 24-well plates (500 μl per well).
2) The messenger RNA nanoparticles prepared in Example 2 were diluted in OPTI-MEMI (Gibco), and then TransIT-X2 (Mirus), a transfection reagent, was further added and incubated at room temperature for 15 minutes, The mRNA-NPs complex forms a mRNA-NPs complex in which the transit-X2 envelopes the positively charged mRNA-NPs.
3) After forming mRNA-NPs complex, 2.10 × 10 5 mRNA-NPs are diluted in each well of the cells, and the cells are cultured in a humidified atmosphere with 5% CO 2 at 37 ° C. for 3 to 48 hours .
4) To obtain images of PC-3 cells expressing GFP, the cells are grown in 8-well cell culture chamber slides (SPL Life Science). All cells were fixed with 4% paraformaldehyde (MBiotech) and stained with 5 μg ml -1 of DAPI to confirm the position of the nucleus. A fluorescence microscope (Eclipse Ti (Nikon)) was used to obtain images of the transfected cells, the results of which are shown in Figures 8 and 9. 8 (a) and 8 (b) are fluorescence micrographs using different filters, showing the position of the nucleus from the blue color of a) and the GFP protein expression from the green signal of b). Bottom (mRNA-NPs) in FIGS. 8 a) and b) were fluorescence micrographs of cells treated with 0.6 fM mRNA-NPs complex and middle (Plasmid) was the same as that used for the production of mRNA- Top (Control) is a fluorescence microscope photograph of cells in which mRNA-NPs complex and plasmid DNA complex are not used. FIG. 8C is a photograph together showing the signals of a) and b). FIG. 9 is a fluorescence microscope photograph of cells treated with mRNA-NPs 0.1 fM produced by using 5 nM of plasmid DNA for rolling circle transfer. It is a composite of photographs taken using a filter.
5). It can be seen from FIG. 8 that the transgenic cells using transgenic RNA nanoparticles have a high frequency of emitting green light, so that a large number of green fluorescent proteins are generated (see mRNA-NPs). Plasmid DNA is used Transfected cells have a relatively low frequency of emitting green light, indicating that less green fluorescence protein is produced (see Plasmid). In FIG. 9, it can be seen that the transgenic RNA nanoparticles were used to transduce a green fluorescent protein (green) around the nucleus (blue).
FIG. 10 is a graph showing Cytometry analysis. As a graph showing the cytotoxic analysis, a sample (12 pM (navy) of plasmid DNA complex, 0.6 fM (red) and 0.1 fM (orange) of mRNA-NPs complex transcribed with 1 nM of the plasmid DNA), the intensity of light emitted and the time of expression vary. FIG. 10 shows that when the mRNA-NPs complex 0.6 fM is transfected, the intensity of light is strongest after 24 hours and the intensity is relatively strong after 40 hours (see red line). That is, when the herpes simplex RNA nanoparticles are transfected with the plasmid DNA, the intensity of the light is strong and the expression time is prolonged.
While the present invention has been described in connection with what is presently considered to be practical exemplary embodiments, it is to be understood that the invention is not limited to the disclosed embodiments, but, on the contrary, Should be interpreted as belonging to the scope.
<110> University of Seoul Industry Coopreation Foundation <120> mRNA nanoparticles and manufacturing method thereof <130> PDAHJ-15157 <160> 3 <170> Kopatentin 2.0 <210> 1 <211> 717 <212> DNA <213> Artificial Sequence <220> <223> region of plasmid DNA for protein generation <400> 1 ctatttgtat agttcatcca tgccatgtgt aatcccagca gctgttacaa actcaagaag 60 gaccatgtgg tctctctttt cgttgggatc tttcgaaagg gcagattgtg tggacaggta 120 atggttgtct ggtaaaagga cagggccatc gccaattgga gtattttgtt gataatggtc 180 tgctagttga acgcttccat cttcaatgtt gtgtctaatt ttgaagttaa ctttgattcc 240 attcttttgt ttgtctgcca tgatgtatac attgtgtgag ttatagttgt attccaattt 300 gtgtccaaga atgtttccat cttctttaaa atcaatacct tttaactcga ttctattaac 360 aagggtatca ccttcaaact tgacttcagc acgtgtcttg tagttcccgt catctttgaa 420 aaatatagtt ctttcctgta cataaccttc gggcatggca ctcttgaaaa agtcatgccg 480 tttcatatga tctgggtatc ttgaaaagca ttgaacacca taagagaaag tagtgacaag 540 tgttggccat ggaacaggta gttttccagt agtgcaaata aatttaaggg taagttttcc 600 gtatgttgca tcaccttcac cctctccact gacagaaaat ttgtgcccat taacatcacc 660 atctaattca acaagaattg ggacaactcc agtgaaaagt tcttctcctt tactcat 717 <210> 2 <211> 10 <212> DNA <213> Artificial Sequence <220> <223> region of plasmid DNA for binding eukaryotic ribosomal <400> 2 ccatggtggc 10 <210> 3 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> promoter region of plasmid DNA for RNA polymerase <400> 3 atccctatag tgagtcgtat ta 22
Claims (10)
The method comprises the steps of: generating a DNA comprising a nucleotide sequence containing genetic information for expression of a specific protein; A transcription step of transcribing said DNA with an RNA polymerase to produce one kind of single-stranded messenger RNA comprising a repeated base sequence for expression of a specific protein; And a self-assembly step of incubating the reaction solution containing the single-stranded messenger RNA of the above type at a predetermined temperature for a predetermined time to form messenger RNA nanoparticles through self-assembly while the single-stranded messenger RNA twists and tangles with each other Since the messenger RNA nanoparticles are resistant to the nucleic acid degrading enzyme RNase, they do not undergo the capping process at the 5 'end and the polyadenylation process at the 3' end,
In the DNA production step, a circular double-stranded plasmid DNA comprising a promoter region sequence for polymerization of an RNA polymerase, a ribosome-binding base sequence and a nucleotide sequence containing genetic information for the expression of a specific protein is sequentially generated ,
1 to 5 nM is used as the plasmid DNA in the transcription step,
Wherein the messenger RNA nanoparticles have a spherical shape and have a diameter of 90 to 110 nm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150134281A KR101751804B1 (en) | 2015-09-23 | 2015-09-23 | mRNA nanoparticles and manufacturing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150134281A KR101751804B1 (en) | 2015-09-23 | 2015-09-23 | mRNA nanoparticles and manufacturing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170035450A KR20170035450A (en) | 2017-03-31 |
| KR101751804B1 true KR101751804B1 (en) | 2017-06-28 |
Family
ID=58500805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150134281A KR101751804B1 (en) | 2015-09-23 | 2015-09-23 | mRNA nanoparticles and manufacturing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101751804B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102212465B1 (en) * | 2019-01-16 | 2021-02-03 | 서울시립대학교 산학협력단 | Method for preparing vesicles by delivery of RNA nanoparticles and vesicles prepared therefrom |
-
2015
- 2015-09-23 KR KR1020150134281A patent/KR101751804B1/en active IP Right Grant
Non-Patent Citations (3)
| Title |
|---|
| Daehoon Han 등. Nature Communications 5. Article No. 4367, 페이지 1-7 (2014.)* |
| Shu Y et al., Adv Drug Deliv Rev. Vol.66, pp.74-89. (Epub 2013. 11. 22.) |
| 김혜진 등. 한국공업화학회 춘계학술대회. 페이지 187, IP-131 (2014.04.30.)* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170035450A (en) | 2017-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Washbourne et al. | Techniques for gene transfer into neurons | |
| Liu et al. | Preparation of fluorescence starch-nanoparticle and its application as plant transgenic vehicle | |
| KR101776368B1 (en) | mRNA nanoparticles and manufacturing method thereof | |
| US9267150B2 (en) | Supercoiled minicircle DNA for gene therapy applications | |
| EP3199633B1 (en) | Downregulation of gene expression using particles charged with nucleic acid similar to viruses | |
| Boukany et al. | Nonendocytic delivery of lipoplex nanoparticles into living cells using nanochannel electroporation | |
| CN113227152A (en) | Programmable design factor therapeutic fusogenic secreted g-type extranuclear granule vesicles for macromolecule delivery and genomic modification | |
| US20220233462A1 (en) | Biodegradable multilayer nanocapsules for the delivery of biologically active agents in target cells | |
| CN110885789A (en) | Preparation of engineered exosome of efficient controllable packaging endogenous nucleic acid and application thereof | |
| CA3164176A1 (en) | Nucleic acid loaded red blood cell extracellular vesicles | |
| WO2024050923A1 (en) | Neuronal transfection method based on adipose-derived exosomes and use thereof | |
| KR101751804B1 (en) | mRNA nanoparticles and manufacturing method thereof | |
| CN112941072B (en) | Nucleic acid self-assembly structure and preparation method and application thereof | |
| CN113226336A (en) | Method for delivering gene in cell | |
| KR102122336B1 (en) | Method for preparing iPSCs using RNA nanoparticle | |
| CN111154808B (en) | Gene transporter and preparation method and application thereof | |
| JP6961162B2 (en) | Method for producing microvesicles by transmitting RNA nanoparticles | |
| KR101533059B1 (en) | Method for preparing polymeric siRNA via rolling circle transcription and the polymeric siRNA prepared thereof | |
| WO2023074873A1 (en) | Cell purification method | |
| JP5594838B2 (en) | Oligonucleotide structure and gene expression control method | |
| KR20230056851A (en) | Composition for inducing direct conversion comprising self-assembled RNA construct | |
| Zhang | Bussmann | |
| He et al. | Engineered exosomes targeting technology and potential in the field of peripheral nerve injury repair. | |
| CN117625546A (en) | Method for improving T cell efficiency | |
| KR20160049295A (en) | RNA particles and manufacturing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |